Medivir AB – Interim Report January – March 2024
Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months.
Medivir AB – Interim Report January – March 2024 Read More »
